Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study
Main finding · Incident dementiaResult — go to the resultAdjusted hazard ratio 0.78 95% CI 0.55–1.12Authors' conclusion
Primary findings did not yield conclusive evidence to infer an association between SGLT-2i use and the risk of incident dementia.
Study context
- Population
- Individuals with T2D aged ≥40 years, newly prescribed SGLT2i or DPP-4i 2013–2021, Clinical Practice Research Datalink (CPRD) Aurum database, UK
- Participants
- 118,006 individuals
- Exposure
- SGLT2i vs DPP-4i
- Outcome
- Incident dementia
Methodological detailspropensity score fine stratification weights
- Propensity score fine stratification weights
Main finding
As reported in the abstract
Adjusted hazard ratio
0.78
95% CI 0.55–1.12
By group
SGLT2i
0.56/1000 person-years
DPP-4i
2.67/1000 person-years
SGLT2ivs DPP-4i
adjusted HR 0.78 (95% CI 0.55–1.12)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Adjusted HR (95% CI) | |
|---|---|---|
| Incident mild cognitive impairment (MCI) | 0.86 (0.80–0.92) | |
| Incident dementia, aged ≥65 yearsAge-specific stratified analysis | 0.50 (0.31–0.80) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Original publication
Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study. BMJ Open Diabetes Res Care. Published 21 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →